Lion TCR
Singapore
About Lion TCR
They are a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases in Asia. For the past decade, they have accumulated expertise covering the entire product development process, ranging from basic research, T cell engineering and development, and preclinical/clinical assessment. Led by industry and academic experts from their base in Singapore, they are dedicated to the commercialization and continued development of their immunotherapy products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $61.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2023)
- Website: liontcr.com
- Phone: +65 6586 9633
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/lion-tcr-34850 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.